Clinical Trial Update: Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of SRF617 in combination with AB928 (etrumadenant) and AB122 (zimberelimab) for metastatic castration-resistant prostate cancer was terminated; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• AB122
• AB928
• SRF617

Snippet

Sponsor: Coherus Oncology, Inc. | Conditions: Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-05-17